DEST Stock Overview
A biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Destiny Pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.16 |
| 52 Week High | UK£0.84 |
| 52 Week Low | UK£0.13 |
| Beta | 0.31 |
| 1 Month Change | -13.70% |
| 3 Month Change | -62.05% |
| 1 Year Change | -52.99% |
| 3 Year Change | -88.11% |
| 5 Year Change | -80.06% |
| Change since IPO | -92.76% |
Recent News & Updates
Recent updates
We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely
Jan 12
Destiny Pharma (LON:DEST) Is In A Good Position To Deliver On Growth Plans
Sep 26We Think Destiny Pharma (LON:DEST) Needs To Drive Business Growth Carefully
May 26Companies Like Destiny Pharma (LON:DEST) Are In A Position To Invest In Growth
Feb 01Will Destiny Pharma (LON:DEST) Spend Its Cash Wisely?
Aug 05Is Destiny Pharma (LON:DEST) In A Good Position To Invest In Growth?
Apr 16What Type Of Shareholders Make Up Destiny Pharma plc's (LON:DEST) Share Registry?
Feb 11
We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely
Nov 30Shareholder Returns
| DEST | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -7.4% | -0.1% | 0.1% |
| 1Y | -53.0% | -21.6% | 6.4% |
Return vs Industry: DEST underperformed the UK Biotechs industry which returned -19.3% over the past year.
Return vs Market: DEST underperformed the UK Market which returned 6.7% over the past year.
Price Volatility
| DEST volatility | |
|---|---|
| DEST Average Weekly Movement | 13.7% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: DEST's share price has been volatile over the past 3 months.
Volatility Over Time: DEST's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO |
|---|---|---|
| 1996 | 24 | Chris Tovey |
| Website |
|---|
| www.destinypharma.com |
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Research/Biofilms that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections.
Destiny Pharma plc Fundamentals Summary
| DEST fundamental statistics | |
|---|---|
| Market cap | UK£15.01m |
| Earnings (TTM) | -UK£5.66m |
| Revenue (TTM) | UK£831.55k |
18.1x
P/S Ratio-2.7x
P/E RatioIs DEST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DEST income statement (TTM) | |
|---|---|
| Revenue | UK£831.55k |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£831.55k |
| Other Expenses | UK£6.49m |
| Earnings | -UK£5.66m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.059 |
| Gross Margin | 100.00% |
| Net Profit Margin | -680.30% |
| Debt/Equity Ratio | 0% |
How did DEST perform over the long term?
See historical performance and comparison